AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
On NOV 13 2025,
(ZEC) rose by 5.93% within 24 hours to $524.73, according to updated market data. Over the past week, the asset has declined by 10.98%, but over the last month and year, it has gained 32.18% and 850.45%, respectively. These figures place in the spotlight as one of the top-performing altcoins, particularly within the privacy-focused digital asset segment.The surge coincided with the rebranding of Leap Therapeutics to Cypherpunk Technologies, a move that has solidified the company’s focus on Zcash as a core treasury asset. The firm announced the purchase of 203,775.27 ZEC for a total of $50 million, averaging $245.37 per token. This acquisition represents approximately 1.25% of the circulating ZEC supply and positions Cypherpunk to accumulate up to 5% of the total supply in the future. The move is backed by Winklevoss Capital, which led a $58.88 million private placement in October.
The firm has restructured its leadership to support the new strategy, with Khing Oei appointed as Chairman and Will McEvoy as Chief Investment Officer, both effective November 11. Oei previously founded a Bitcoin-focused euro-denominated treasury firm and has significant experience in managing over $200 million in assets. McEvoy, a principal at Winklevoss Capital, emphasized the company’s departure from short-term capital by forming a syndicate of value-aligned investors focused on long-term Zcash growth.
The rebranding also includes a ticker change to
, effective on November 13. The transition aligns with a broader corporate vision that views privacy as a cornerstone of digital freedom. Zcash’s use of zero-knowledge proofs (zk-SNARKs) allows for private transactions without revealing sender, receiver, or transaction amount—features that have attracted growing institutional interest in the privacy sector.Winklevoss Capital has been vocal in its support, with co-founder Tyler Winklevoss describing Zcash as “encrypted Bitcoin” or “digital cash.” He argues that as
serves as a store of value, Zcash functions as a medium for private value transfer. Winklevoss also anticipates that Zcash could capture a meaningful percentage of Bitcoin’s market capitalization, particularly as AI adoption grows. He has projected that Bitcoin could reach $1 million per coin over the next five to ten years, implying significant upside potential for Zcash as well.Zcash’s technical performance has mirrored the broader trend. The asset has seen a parabolic rally since September, peaking at an all-time high of $750 on October 30. However, it followed a market-wide correction that saw its price fall over 40% to around $420 before rebounding. As of NOV 13, ZEC is trading above $500, with technical indicators suggesting a possible continuation of the uptrend if key resistance levels are breached.
To evaluate the potential effectiveness of a Zcash-based investment strategy amid recent price fluctuations, one could test a specific event-driven approach. This backtest would focus on “-10% daily drop” events from January 1, 2022, to the present. The test assumes ZEC is the only asset under analysis, and the triggering event is defined as a close-to-close price drop of at least -10% on a given trading day. After the drop, the strategy would hold the asset for a fixed number of days—say, 10 trading days—before exiting the position, regardless of performance.
The hypothesis is that Zcash, given its high volatility and strong institutional backing, may show resilience after significant daily drops. This could create opportunities for strategic long positions to capture rebounds or extended upward momentum in the following days. The backtest would also evaluate the role of stop-loss and take-profit thresholds in controlling downside risk and locking in gains.
Delivering real-time analysis and insights on unexpected cryptocurrency price movements to keep traders ahead of the curve.

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025

Dec.05 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet